Results 111 to 120 of about 7,521 (213)

Icteric flare of chronic hepatitis B in a 95-year old patient [PDF]

, 2003
A 95-year old gentleman developed fatal icteric flare of chronic hepatitis B despite lamivudine treatment. This article highlights the atypical presentations of chronic hepatitis B in elderly patient and the need to consider this possibility for acute ...
Chan, HLY, Leung, WK, Wong, WS
core   +1 more source

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B [PDF]

, 2003
YMDD variants of hepatitis B virus (HBV) emerge in some patients with chronic hepatitis B who receive lamivudine. YMDD variants were examined in 794 patients in 4 controlled studies of 1 year's duration.
Atkins, M, Boehme, R, Brown, N, Condreay, L, Dienstag, J, Hunt, C, Lai, CL, Leung, NWY, Schiff, E, Woessner, M   +9 more
core   +1 more source

An Observational Study to Evaluate the Safety and Efficacy of Telbivudine in Adults with Chronic Hepatitis B

Acta Medica Indonesiana, 2016
Aim: to assess the safety and efficacy of telbivudine therapy in adult patients with CHB in Indonesia. Methods: the study design was prospective cohort study.
Ali Sulaiman, Laurentius A Lesmana, Nafrialdi Nafrialdi, Helyanna Helyanna   +3 more
doaj   +4 more sources

Favorable Response to Long-term Nucleos(t)ide Analogue Therapy in HBeAg-positive Patients with High Serum Fucosyl-Agalactosyl IgG

Scientific Reports, 2017
Aberrant IgG glycosylation is a feature of hepatitis B virus (HBV) infection but its effect on a long-term efficacy of antiviral therapy has never been addressed.
Cheng-Hsun Ho, Hung-Wen Tsai, Chen-Yeh Lee, Li-Juan Huang, Rong-Nan Chien, I-Chin Wu, Yen-Cheng Chiu, Wen-Chun Liu, Pin-Nan Cheng, Ting-Tsung Chang, Shu-Hui Chen   +10 more
doaj   +1 more source

Using machine learning models to predict HBeAg seroconversion in CHB patients receiving pegylated interferon-α monotherapy. [PDF]

J Clin Lab Anal, 2022
Shang H, Hu Y, Guo H, Lai R, Fu Y, Xu S, Zeng Y, Xun Z, Liu C, Wu W, Guo J, Ou Q, Chen T.   +12 more
europepmc   +1 more source

Seroconversion of HBsAg in HBeAg positive and HBeAg negative patients with chronic HBV treated with entecavir: a case series.

European review for medical and pharmacological sciences, 2010
We report a case series of three HBeAg positive and five HBeAg negative patients (7 males, mean age 50.6 +/- 14.6 years) with chronic HBV infection experiencing seroconversion after treatment with entecavir (0.5 mg/day or 1 mg/day), initiated in 2007. Overall, the mean time to HBsAg clearance was 9.4 +/- 4.5 months.
G. D'Ettorre, G. Barbarini, F. Corti, M. Gobber, C. Pastecchia, G. L. Ricci, M. Siciliano, B. E. Annicchiarico, VULLO, Vincenzo   +8 more
openaire   +2 more sources

The decline of HBV RNA associated with HBeAg seroconversion and double-negative HBV DNA and RNA in chronic hepatitis B patients who received entecavir therapy: a 10-year retrospective cohort study. [PDF]

Ann Transl Med, 2022
Ye F, Zhao W, Yang X, Zhang X, An X, Zhu R, Chen Y, Liu X, Li J, Li K, Zheng J, Lin S, Shi L.   +12 more
europepmc   +1 more source

Characterization of long-term natural outcome of chronic hepatitis B virus infections [PDF]

, 2016
慢性乙型肝炎病毒感染是世界重要的公共卫生问题，可以导致肝癌、肝硬化等终末期肝病，继而导致死亡。我国是慢乙肝高流行区，全国约有1.2亿的慢性HBV携带者，慢性乙肝患者约3000万例，HBV感染对我国国民健康造成严重威胁。本研究的主要目的在于研究自然人群慢乙肝感染者的长期转归及其相关因素，监测乙肝相关肝硬化和肝癌的发病率，并且研究成人接种乙肝疫苗对其新感染的保护以及终末期肝病发生的影响。有助于更加深入的了解和认识乙肝，并为预防和预测乙肝相关终末期肝病提供重要的数据和依据 ...
杨林
core  

Development and validation of a multivariable nomogram predictive of hepatitis B e antigen seroconversion after pregnancy in hepatitis B virus-infected mothers

Frontiers in Medicine
Background and aimsCurrent guidelines are controversial regarding the continuation of nucleos(t)ide analogues (NAs) therapy after delivery in Hepatitis B virus (HBV)-infected pregnant women.
Wenting Zhong, Jie Zheng, Che Wang, Lei Shi, Yingli He, Yingren Zhao, Tianyan Chen   +6 more
doaj   +1 more source

Plasma Level of ADAMTS13 or IL-12 as an Indicator of HBeAg Seroconversion in Chronic Hepatitis B Patients Undergoing m-ETV Treatment. [PDF]

Front Cell Infect Microbiol, 2020
Yang J, Guo R, Yan D, Lu H, Zhang H, Ye P, Jin L, Diao H, Li L.   +8 more
europepmc   +1 more source